7. Company Strategies of Global R&D Collaborations: From West Meets West to West Meets East
“The success of our FIPNet strategy is inextricably tied to the success of our partners, and our network is only as strong as our partners.”
—John Lechleiter, CEO, Eli Lilly and Company1
Global Biopharma Industry Changes As It Interfaces with New Players
The biopharma industry used to be a club of companies from the United States, Europe, and Japan. Those companies are often classified into distinctive groups. The most important group is the so-called “big pharma,” the top dozen or so truly big global players. The second group includes the smaller “mid pharma” companies. The generics companies and the newly arrived large biotechnology (biologics) companies ...